Nov. 10 Quick Takes: Genomics England shows sequencing can improve outcomes

Genomics England published a first of its kind study to determine whether whole genome sequencing could improve the diagnostic outcomes across a range of rare diseases. The pilot sub-study, part of the 100,000 Genomes Project, enrolled 4,660 participants that had 161 different rare diseases but had not received a genomic diagnosis despite many receiving a variety of tests. Whole genome sequencing was able to provide a genetic diagnosis for 25% of participants that had an immediate impact on clinical decision-making. The study also uncovered three new disease-causing genes and 19 new associations.

Novome Biotechnologies Inc. and Genentech Inc. will use Novome’s Genetically Engineered Microbial Medicines (GEMMs) technology to discover, engineer and develop bacterial strains that deliver specific therapeutically relevant molecules to the human intestinal tract to treat inflammatory bowel disease and other indications. Novome will receive $15 million up front and is eligible for $590 million in milestones, plus royalties...